FDA Approval of Olaparib for Certain Breast Cancers

The U.S. Food and Drug Administration (FDA) has approved the expansion of the indications of the anti-cancer drug olaparib. Olaparib can now be used to treat patients with certain breast cancers that have spread and where the tumors are caused by a specifically inherited genetic mutation called BRCA mutation. Olaparib is the first drug in its class, a PARP protein inhibitor, to be approved to treat breast cancer and specifically for such an indication.